10 Best Immunotherapy Stocks to Buy Now
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.
Bristol Myers Squibb Co (BMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pzena Investment Management Richard S. Pzena | 14,201,746 | $734,798,338 | +1% | 2.36% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 9,550,500 | $494,142,870 | -16% | 1.15% |
| 3. | 7,139,900 | $369,418,426 | +25% | 0.07% | |
| 4. | 6,918,500 | $357,963,190 | -22% | 0.06% | |
| 5. | Millennium Management Israel Englander | 5,185,435 | $268,294,407 | +248% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $54.68 | 1,830 | Officer | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | Officer | 82,672 | 2023-12-05 | Filing | |
| $48.86 | 3,071 | Officer | 79,384 | 2023-11-28 | Filing | |
| $49.81 | 8,500 | Director | 35,500 | 2023-11-20 | Filing | |
| $54.50 | 9,174 | Director | 22,109 | 2020-06-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $55.62 | 700 | Officer | 11,760 | 2024-11-04 | Filing | |
| $61.25 | 17,986 | Officer | 27,868 | 2023-08-24 | Filing | |
| $61.14 | 732 | Officer | 6,584 | 2023-08-03 | Filing | |
| $67.06 | 50,385 | Officer | 47,751 | 2023-05-03 | Filing | |
| $74.65 | 240,000 | Officer, Director | 236,104 | 2023-02-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 198,159,772 | $10,167,577,900 | 0.22% | |
| 2. | 168,103,766 | $8,625,404,241 | 0.21% | |
| 3. | 90,048,274 | $4,620,376,928 | 0.49% | |
| 4. | 89,446,206 | $4,589,484,830 | 0.22% | |
| 5. | 61,528,492 | $3,156,982,203 | 0.7% |
News See All
Dividend Contenders List: Top 15
Dividend stocks have long been favored by investors for the income they generate, and they become even more appealing when dividends increase over time.
10 Best Pharma Stocks To Buy Right Now
Healthcare takes the concept of 'defensive' further than almost any industry, encompassing many companies that provide patient care, engage in the research and development of new treatments, and design...
Bristol-Myers Squibb Company (NYSE:BMY) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Bristol-Myers Squibb Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Jim Cramer’s Latest Game Plan: 20 Stocks to Watch
Jim Cramer, the host of Mad Money, recently advised investors to maintain composure as major companies release their earnings this week.
Bristol-Myers Squibb Company (BMY): A Bull Case Theory
We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BMY.
10 Best Medical Stocks to Buy Now
The medical and healthcare industry is one of the largest globally, with a steady demand for products and services due to the biological nature of humans. Stocks like Pfizer Inc.
Jim Cramer's Exclusive List of 9 YEV Stocks
To navigate this market, he developed a three-part evaluation framework, which he refers to as the YEV test.
10 Buzzing AI Health Stocks
The economic impact of AI is projected to be substantial, particularly in regions like China and North America, which are expected to see GDP boosts of 26% and 14.5%, respectively, by 2030, amounting ...
Dividend Achievers List: Top 15
Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.